European Union

Novartis Gains EU Approval for Kisqali® to Broaden Early Breast Cancer Treatment Options

(IN BRIEF) Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an adjuvant…

11 months ago